Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation.
In vivo GITR ligation has previously been shown to augment T-cell-mediated anti-tumor immunity, yet the underlying mechanisms of this activity, particularly its in vivo effects on CD4+ foxp3+ regulatory T cells (Tregs), have not been fully elucidated. In order to translate this immunotherapeutic approach to the clinic it is important gain better understanding of its mechanism(s) of action. Utilizing the agonist anti-GITR monoclonal antibody DTA-1, we found that in vivo GITR ligation modulates regulatory T cells (Tregs) directly during induction of melanoma tumor immunity. As a monotherapy, DTA-1 induced regression of small established B16 melanoma tumors. Although DTA-1 did not alter systemic Treg frequencies nor abrogate the intrinsic suppressive activity of Tregs within the tumor-draining lymph node, intra-tumor Treg accumulation was significantly impaired. This resulted in a greater Teff:Treg ratio and enhanced tumor-specific CD8+ T-cell activity. The decreased intra-tumor Treg accumulation was due both to impaired infiltration, coupled with DTA-1-induced loss of foxp3 expression in intra-tumor Tregs. Histological analysis of B16 tumors grown in Foxp3-GFP mice showed that the majority of GFP+ cells had lost Foxp3 expression. These "unstable" Tregs were absent in IgG-treated tumors and in DTA-1 treated TDLN, demonstrating a tumor-specific effect. Impairment of Treg infiltration was lost if Tregs were GITR(-/-), and the protective effects of DTA-1 were reduced in reconstituted RAG1(-/-) mice if either the Treg or Teff subset were GITR-negative and absent if both were negative. Our results demonstrate that DTA-1 modulates both Teffs and Tregs during effective tumor treatment. The data suggest that DTA-1 prevents intra-tumor Treg accumulation by altering their stability, and as a result of the loss of foxp3 expression, may modify their intra-tumor suppressive capacity. These findings provide further support for the continued development of agonist anti-GITR mAbs as an immunotherapeutic strategy for cancer.
Cohen
Adam D
AD
Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America.
Schaer
David A
DA
Liu
Cailian
C
Li
Yanyun
Y
Hirschhorn-Cymmerman
Daniel
D
Kim
Soo Chong
SC
Diab
Adi
A
Rizzuto
Gabrielle
G
Duan
Fei
F
Perales
Miguel A
MA
Merghoub
Taha
T
Houghton
Alan N
AN
Wolchok
Jedd D
JD
D019264:Adoptive Transfer; D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology*; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D051858:Forkhead Transcription Factors / Q000378:metabolism; D053450:Glucocorticoid-Induced TNFR-Related Protein; D007109:Immunity / Q000276:immunology*; D016246:Lymphocytes, Tumor-Infiltrating / Q000276:immunology; D008545:Melanoma / Q000276:immunology* / Q000473:pathology; D051379:Mice; D008810:Mice, Inbred C57BL; D017475:Receptors, Nerve Growth Factor / Q000819:agonists* / Q000276:immunology*; D018124:Receptors, Tumor Necrosis Factor / Q000819:agonists* / Q000276:immunology*; D050378:T-Lymphocytes, Regulatory / Q000276:immunology*; D015854:Up-Regulation / Q000276:immunology
D000911:Antibodies, Monoclonal; D051858:Forkhead Transcription Factors; C498833:Foxp3 protein, mouse; D053450:Glucocorticoid-Induced TNFR-Related Protein; D017475:Receptors, Nerve Growth Factor; D018124:Receptors, Tumor Necrosis Factor; C106544:Tnfrsf18 protein, mouse
Nat Rev Immunol. 2008 Jul;8(7):523-32
18566595
Nat Immunol. 2009 Sep;10(9):1000-7
19633673
Biochem Biophys Res Commun. 2008 May 16;369(4):1134-8
18346459
J Immunol Methods. 2003 Oct 1;281(1-2):65-78
14580882
J Immunol. 2005 Jun 15;174(12):7869-74
15944292
Proc Natl Acad Sci U S A. 2008 Apr 8;105(14):5465-70
18378892
Nature. 2007 Feb 15;445(7129):771-5
17220874
Nat Immunol. 2009 Nov;10(11):1178-84
19783988
J Exp Med. 2008 Apr 14;205(4):825-39
18362171
J Immunol. 2004 Oct 15;173(8):5008-20
15470044
Blood. 2006 Jul 15;108(2):426-31
16537800
J Exp Med. 2005 Oct 3;202(7):885-91
16186187
Cancer Res. 2008 Jul 15;68(14):5948-54
18632650
J Exp Med. 1995 Nov 1;182(5):1609-14
7595233
Blood. 2002 Jul 1;100(1):350-2
12070049
J Immunol. 2004 Apr 15;172(8):4686-90
15067043
J Immunol. 2009 Jan 1;182(1):259-73
19109157
Eur J Immunol. 2004 Feb;34(2):447-54
14768049
Eur J Immunol. 2005 Apr;35(4):1016-22
15770698
Blood. 2005 Nov 1;106(9):3097-104
16014565
J Immunol. 2008 Mar 1;180(5):2757-61
18292494
Proc Natl Acad Sci U S A. 2009 Feb 10;106(6):1903-8
19174509
J Immunol. 2007 Dec 1;179(11):7365-75
18025180
Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):15059-64
14608036
J Exp Med. 2004 Feb 2;199(3):303-13
14757740
Curr Opin Immunol. 2009 Jun;21(3):281-5
19500966
Immunity. 2004 Mar;20(3):293-303
15030773
Nat Immunol. 2007 Mar;8(3):277-84
17220892
Nat Med. 2004 Sep;10(9):942-9
15322536
J Immunol. 2006 Mar 15;176(6):3507-15
16517719
J Immunol. 2006 Jun 1;176(11):6434-42
16709800
Cancer Res. 2006 May 1;66(9):4904-12
16651447
Blood. 2008 Jan 15;111(2):761-6
17967942
Nat Immunol. 2002 Feb;3(2):135-42
11812990
Immunol Today. 1997 Oct;18(10):472-7
9357138
Nature. 2007 Feb 15;445(7129):766-70
17220876
J Exp Med. 2003 Aug 18;198(4):569-80
12925674
J Clin Invest. 2006 Jul;116(7):1935-45
16778987
J Virol. 2005 Sep;79(18):11935-42
16140769
J Exp Med. 2004 Jul 19;200(2):149-57
15249593
Exp Hematol. 2006 Aug;34(8):1033-40
16863909
J Exp Med. 2009 Aug 3;206(8):1717-25
19581407
J Immunol. 2004 Jun 15;172(12):7306-14
15187106
Immunity. 2005 Mar;22(3):329-41
15780990
Cancer Res. 2008 Jul 1;68(13):5206-15
18593921
Blood. 2005 Apr 1;105(7):2845-51
15591118
Eur J Immunol. 2004 Mar;34(3):613-622
14991590
J Exp Med. 2004 Sep 20;200(6):771-82
15381730
Immunity. 2002 Feb;16(2):311-23
11869690